Cargando…
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854441/ https://www.ncbi.nlm.nih.gov/pubmed/30816809 http://dx.doi.org/10.2217/fon-2019-0013 |
_version_ | 1783470215155154944 |
---|---|
author | Costello, Caitlin Davies, Faith E Cook, Gordon Vela-Ojeda, Jorge Omel, Jim Rifkin, Robert M Berdeja, Jesus Puig, Noemi Usmani, Saad Z Weisel, Katja Zonder, Jeffrey A Terpos, Evangelos Spencer, Andrew Leleu, Xavier Boccadoro, Mario Thompson, Michael A Romanus, Dorothy Stull, Dawn M Hungria, Vania |
author_facet | Costello, Caitlin Davies, Faith E Cook, Gordon Vela-Ojeda, Jorge Omel, Jim Rifkin, Robert M Berdeja, Jesus Puig, Noemi Usmani, Saad Z Weisel, Katja Zonder, Jeffrey A Terpos, Evangelos Spencer, Andrew Leleu, Xavier Boccadoro, Mario Thompson, Michael A Romanus, Dorothy Stull, Dawn M Hungria, Vania |
author_sort | Costello, Caitlin |
collection | PubMed |
description | With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187 |
format | Online Article Text |
id | pubmed-6854441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-68544412019-11-20 INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma Costello, Caitlin Davies, Faith E Cook, Gordon Vela-Ojeda, Jorge Omel, Jim Rifkin, Robert M Berdeja, Jesus Puig, Noemi Usmani, Saad Z Weisel, Katja Zonder, Jeffrey A Terpos, Evangelos Spencer, Andrew Leleu, Xavier Boccadoro, Mario Thompson, Michael A Romanus, Dorothy Stull, Dawn M Hungria, Vania Future Oncol Clinical Trial Protocol With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187 Future Medicine Ltd 2019-05 2019-02-28 /pmc/articles/PMC6854441/ /pubmed/30816809 http://dx.doi.org/10.2217/fon-2019-0013 Text en © 2019 Caitlin Costello This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Clinical Trial Protocol Costello, Caitlin Davies, Faith E Cook, Gordon Vela-Ojeda, Jorge Omel, Jim Rifkin, Robert M Berdeja, Jesus Puig, Noemi Usmani, Saad Z Weisel, Katja Zonder, Jeffrey A Terpos, Evangelos Spencer, Andrew Leleu, Xavier Boccadoro, Mario Thompson, Michael A Romanus, Dorothy Stull, Dawn M Hungria, Vania INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
title | INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
title_full | INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
title_fullStr | INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
title_full_unstemmed | INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
title_short | INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
title_sort | insight mm: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma |
topic | Clinical Trial Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854441/ https://www.ncbi.nlm.nih.gov/pubmed/30816809 http://dx.doi.org/10.2217/fon-2019-0013 |
work_keys_str_mv | AT costellocaitlin insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT daviesfaithe insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT cookgordon insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT velaojedajorge insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT omeljim insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT rifkinrobertm insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT berdejajesus insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT puignoemi insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT usmanisaadz insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT weiselkatja insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT zonderjeffreya insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT terposevangelos insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT spencerandrew insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT leleuxavier insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT boccadoromario insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT thompsonmichaela insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT romanusdorothy insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT stulldawnm insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma AT hungriavania insightmmalargeglobalprospectivenoninterventionalrealworldstudyofpatientswithmultiplemyeloma |